CELL RECEPTOR DEVELOPS A NOVEL THERAPY FOR HIGH MEDICAL NEED:
CANCER AND AUTOIMMUNE DISEASES.
Cell Receptor, an emerging R&D company based in Kiel, has been researching cell biological processes for years, enabling groundbreaking clinical advances in oncology and autoimmune diseases.
Existing cancer treatments are often associated with severe side effects and, after an initial response from the tumour, usually prove to be insufficiently effective in the long term. The resulting chemoresistance is regularly accompanied by metastasis, which can be fatal. To grow, cells, including tumor cells, depend on a signaling process that occurs outside the cell. Well supplied from outside, cancer cells can often circumvent the effects of cancer drugs. We attack this process outside the cell with well-tolerated agents, thereby blocking both metastasis and chemoresistance.
This signalling process is the same for all growing cells at one point. This point is a bottleneck that can be plugged with well-tolerated agents.
Our well-tolerated method will herald a new era in oncology by reducing unwanted side effects of treatment and preventing the failure of conventional therapy in the majority of cancer cases.
Every growing cell, including tumour cells, needs the presence of platelets to divide. These platelets supply the cells with signaling substances that enable cell growth and also help them evade the immune system. They also protect circulating tumour cells from shear forces. We have discovered how to block contact between cancer cells and blood platelets, thereby preventing the growth of tumour cells and, in particular, metastasis and chemoresistance. In doing so, we have met a twofold urgent need in medicine and opened up promising prospects for the future.
See this article: https://www.nature.com/articles/d43747-021-00133-8
and this: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00742-w
#cellreceptor #cancer treatment #oncology Member of 
promoted by BSFZ 